Thyrocare Technologies Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Thyrocare Technologies Ltd. on BSE

Load latest

Thyrocare Technologies Ltd.

03 Aug 2022

995.20

1.96%

Company Update

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 30, read with Schedule III Part A Para A and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are filing herewith the copies of newspaper advertisement of unaudited financial results for the Quarter ended 30th June 2022, published in Free Press Journal (English) and Pudhari (Marathi) in the prescribed format.

pdf

Thyrocare Technologies Ltd.

02 Aug 2022

995.20

1.96%

Earnings Call

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

We wish to inform you that as already intimated to you in our letter dated July 27, 2022, a conference call for the Indian and Overseas analysts / investors took place at 9.00 a.m. today, to discuss the Company's financial results for Quarter ended June 30, 2022. Mr. Rahul Guha, Managing Director & Chief Executive Officer and Mr. Sachin Salvi, Chief Financial Officer, represented the Management. We confirm that no Unpublished Price Sensitive Information was shared / discussed in the call. We are forwarding audio recording of the conference call. We have also uploaded it on our website. We will be forwarding the transcript shortly.

pdf

Thyrocare Technologies Ltd.

02 Aug 2022

995.20

1.96%

Company Update

Thyrocare Technologies Ltd - 539871 - Outcome Of Board Meeting Held On 01-Aug-2022 To Consider Other …

BSE India

We have already intimated to you about the approval of unaudited financial results for the quarter ended June 30, 2022, by our Board of Directors at their meeting held on August 01, 2022. We wish to inform you that that at this meeting, our Board of Directors also approved the financial results separately prepared for stump period September 02, 2021 to March 31, 2022 (which already forms part of the financial results of the FY 2021-22) for consolidation in the accounts of API Holdings Limited, which is the ultimate holding company of our company. Besides, the Board also approved sharing of any financial details relating to the Company with API Holdings Limited, including unpublished price sensitive information, if any, if so required by them to comply with any statutory requirements.

pdf

Thyrocare Technologies Ltd.

02 Aug 2022

995.20

1.96%

Results Earnings Call for Q1FY23 of Thyrocare Technologies

Conference Call with Thyrocare Technologies Management and Analysts on Q1FY23 Performance and Outlook. Listen to the full earnings transcript.

audio

Thyrocare Technologies Ltd.

01 Aug 2022

995.20

1.96%

Investor Presentation

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

We are forwarding a copy of presentation on Unaudited Financial results for the quarter ended 30 June 2022. Please note that this is only uploaded in our website and not distributed or advertised in newspapers or otherwise publicised.

pdf

Thyrocare Technologies Ltd.

01 Aug 2022

995.20

1.96%

Result

Thyrocare Technologies Ltd - 539871 - Unaudited Financial Results (Stand-Alone And Consolidated) For The Quarter Ended …

BSE India

Pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching the (1) Stand-alone and Consolidated Audited Financial Results for the quarter ended June 30, 2022 and (2) the Limited Audit Review issued by our Auditors.

pdf

Thyrocare Technologies Ltd.

01 Aug 2022

995.20

1.96%

Board Meeting

Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Board Meeting Outcome For Financial Results …

BSE India

The Board of Directors of our company, have approved the Unaudited Financial Results (Stand-alone and consolidated) for the Quarter ended June 30, 2022. Pursuant to Regulation 33 (3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching the (1) Stand-alone and Consolidated Audited Financial Results for the quarter ended June 30, 2022 and (2) the Limited Audit Review issued by our Auditors.

pdf

Thyrocare Technologies Ltd.

27 Jul 2022

995.20

1.96%

Company Update

Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company's financial results for Quarter ended June 30, 2022, on Tuesday, August 02, 2022 at 09:00 am. local time.

pdf

Thyrocare Technologies Ltd.

25 Jul 2022

995.20

1.96%

Board Meeting

Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for Approval Of Financial Results For The …

BSE India

Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Monday August 01, 2022, inter alia, to consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter ended June 30, 2022.

pdf

Thyrocare Technologies Ltd.

18 Jul 2022

995.20

1.96%

Company Update

Thyrocare Technologies Ltd - 539871 - Statement Of Investor Complaints For The Quarter Ended June 2022

BSE India

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ramjee DoraiDesignation :- Company Secretary and Compliance Officer

Is Thyrocare Technologies Ltd. worth buying?

165 Votes:

Buy 76.97%

Sell 12.12%

Hold 10.91%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf